Abstract |
The approval of the first protease inhibitors as treatment for hepatitis C virus (HCV) infection is rapidly transforming the way patients with chronic hepatitis C are managed. Treatment regimens are moving to combinations given for shortened periods, excluding poorly tolerated subcutaneous interferon, and providing rates of cure exceeding 75%. The recognition of HCV infection as a systemic disease, not limited to producing liver damage, in which extrahepatic complications play a major role as the cause of morbidity and mortality, is prompting the treatment of a growing number of HCV-infected individuals. However, new challenges are emerging, including the need to diagnose a substantial proportion of asymptomatic carriers, the risk of potentially harmful drug-drug interactions and the high cost of medications. The future will probably see a progressive marginalization of residual HCV populations, with increasing over-representation of illegal immigrants, alcohol abusers, intravenous drug users and the mentally disabled.
|
Authors | Vincent Soriano, Pablo Labarga, Jose V Fernández-Montero, Jose M Benito, Eva Poveda, Norma Rallon, Clara Sánchez, Eugenia Vispo, Pablo Barreiro |
Journal | Antiviral research
(Antiviral Res)
Vol. 97
Issue 1
Pg. 36-40
(Jan 2013)
ISSN: 1872-9096 [Electronic] Netherlands |
PMID | 23147192
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- Oligopeptides
- telaprevir
- N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
- Proline
|
Topics |
- Antiviral Agents
(administration & dosage, economics)
- Asymptomatic Diseases
- Carrier State
(diagnosis, drug therapy)
- Health Services Accessibility
- Hepatitis C, Chronic
(diagnosis, drug therapy)
- Humans
- Oligopeptides
(administration & dosage, economics)
- Proline
(administration & dosage, analogs & derivatives, economics)
- Treatment Outcome
|